MCK McKesson

McKesson Corporation distributes pharmaceuticals and medical supplies and provides health information technology and care management solutions across North America. Sector: Healthcare.

McKesson (MCK) is an individual stock. The analysis below presents key financial metrics for the company, covering profitability, capital efficiency, valuation, margins, and growth.

Looking at how effectively the company deploy capital, ROIC is 64.08%, WACC is 5.94%, and the economic spread is 58.14%. On balance, the company is earning returns on capital well in excess of what investors and creditors require — the defining characteristic of a high-quality compounding company. Supporting metrics show ROE at N/A and ROA at 5.42%, a combination that helps frame whether profitability strength is broad enough to hold through different market conditions. Taken together, the return profile suggests a company with credible compounding capacity if current operating execution persists.

From a pricing standpoint, the company sits at trailing P/E of 19.79, forward P/E of 17.18, PEG of 1.24. The narrow spread between trailing and forward multiples implies earnings expectations are relatively stable — the company is not being priced for an earnings inflection. Growth-adjusted valuation is compelling at this PEG level — the multiple appears reasonable given the expected earnings trajectory. A current ratio reading of 0.85 suggests the company carries less short-term financial cushion than the broader market average. In total, the multiple and liquidity readings describe a company where valuation is a secondary risk relative to earnings delivery — the numbers are defensible if estimates hold.

Across the three margin layers, gross margin sits at 3.60%, operating margin at 1.58%, and free cash flow margin at 1.38%. The company's gross margins are below average, reflecting sectors where input costs consume the majority of revenue. The company's operating margins are minimal, reflecting a company where overhead costs are not yet well absorbed by revenues. At this level, free cash flow is not a meaningful source of financial flexibility for the company's underlying the company. This margin configuration supports a cautious interpretation: profitability exists, though durability is less certain under stress.

Two key indicators frame the near-term view: TTM revenue growth of 6.02% a signal of steady demand without the volatility of high-growth names, while the estimated 12-month price change of 17.80%, where the target distribution indicates incremental upside rather than outsized repricing. The near-term return case is built on whether reported trends and analyst projections can remain close enough to make current prices look justified. Whether the setup resolves positively or negatively will depend as much on the macro backdrop as on the capacity of the company to deliver against current estimates. The estimated 12-month price change is based on analyst consensus price target estimates, sourced from publicly available data, and should not be interpreted as a reliable prediction of future performance.

The full scorecard here is hard to argue with: capital efficiency is strong, margins are healthy, and growth is being priced constructively.

This summary is based on publicly available quantitative data and is not intended as investment advice. Carefully consider your personal financial circumstances before making any decisions.